Kisspeptin vs PT-141
Emerging vs FDA Approved
monitor Researched · 90% Different pathways (melanocortin vs GnRH) - no receptor overlap but monitor BP effects.
Molecular Data
Kisspeptin PT-141
Weight 1,213.42 Da (KP-10) / 6,087 Da (KP-54) —
Half-life ~4 minutes (KP-10), ~28-32 minutes (KP-54) ~2.7 hours
Chain 10-54 amino acids —
Type Neuropeptide family (RFamide) Melanocortin receptor agonist
Key Benefits
Kisspeptin
01 Potent reproductive hormone stimulation (LH/FSH)
02 Restoration of natural testosterone production
03 Fertility enhancement
04 Sexual function support
05 Hypogonadism treatment potential
PT-141
01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)
Dosing Protocols
Kisspeptin
100-200 mcg per injection / Single dose for testing, or 2-3 times weekly (NEVER daily - causes desensitization)
Gonadotropin stimulation 100-200mcg Single dose or 2-3x weekly
Fertility support 0.4-1.0 nmol/kg (50-150mcg) As directed by physician
Sexual function (clinical) 1 nmol/kg/h 75-minute IV infusion
PT-141
Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance / As needed before sexual activity; max 1 dose per 24 hours
Female HSDD (FDA-approved) 1.75mg As needed, max 1 dose/24hr
Male Erectile Dysfunction 1-2mg As needed, 45-60min before activity
Female Arousal Disorder 0.75-1.25mg As needed, max 1 dose/24hr
Low Starting Dose 0.5mg Test dose for tolerance assessment
Side Effects
Kisspeptin
Minimal acute side effects reported
Potential mild cardiovascular effects
PT-141
Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Contraindications
Not recommended during pregnancy or breastfeeding
Caution with cardiovascular disease history
Daily dosing causes receptor desensitization
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding
Research Evidence
Kisspeptin PT-141
Status Emerging FDA Approved
References 4 studies 4 studies
Latest 2025 2022
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.